摘要
二甲双胍是治疗2型糖尿病药物(T2DM)的一线药物,近年来,其也作为潜在的抗肿瘤药物,被人们进行了广泛的研究。目前了解的二甲双胍抗肿瘤机制多种多样,二甲双胍可以通过AMPK直接或间接调节LKB1/AMPK/mTOR信号通路,诱导ACC磷酸化。也可以通过AMPK的非依赖机制抑制胰岛素受体/IGF-IR信号通路、诱导细胞自噬和凋亡、上调Micro RNAs,以及调节P53/REDD1通路、免疫作用、氧化作用、协同药物治疗等多种机制抑制肿瘤生长。本文将对近年来二甲双胍可能产生的抗肿瘤机制进行分类综述,为其日后相关研究奠定理论基础。
Metformin is a first-line drug for the treatment of type 2 diabetes mellitus(T2DM).In recent years,it has been widely studied as a potential anti-tumor drug.There are various anti-tumor mechanisms currently known for metformin.Metformin can directly or indirectly regulate the LKB1/AMPK/mTOR signaling pathway via AMPK to and induce ACC phosphorylation.Metformin can also inhibit the insulin receptor/IGF-IR signaling pathway via an AMPK-independent mechanism,induce autophagy and apoptosis,up-regulate Micro RNAs,and suppress tumor growth through regulating the P53/REDD1 pathway,exerting immune function,undergoing oxidation,and acting as a synergistic drug therapy.In this paper,the possible anti-tumor mechanisms of metformin in recent years are classified and summarized,which lays a good theoretical foundation for related research in the future.
作者
崔琳琳
王洋
关桦楠
袁甜
申光焕
CUI Lin-lin;WANG Yang;GUAN Hua-nan;YUAN Tian;SHEN Guang-huan(College of Pharmacy,Heilongjiang Provincial Key Laboratory of Prevention and Treatment of Geriatric Drugs,Harbin University of Commerce,Harbin 150076,China;College of Food Engineering,Harbin University of Commerce,Harbin 150076,China)
出处
《现代食品科技》
CAS
北大核心
2021年第8期357-363,共7页
Modern Food Science and Technology
基金
黑龙江省留学回国人员择优资助项目(18930101)
哈尔滨商业大学青年创新人才项目(17XN031)
哈尔滨商业大学博士科研启动项目(2019DS116)。
